CTXR - CIK 0001506251
The table below shows Citius Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$26.55M | -$28.20M | -$29.06M | -$28.36M | -$24.25M | -$16.93M |
| Capital expenditure | - | - | - | - | $6.94K | $1.83K |
| Investing cash flow | -$5.75M | -$5.00M | - | - | -$40.01M | -$1.83K |
| Dividends paid | - | - | - | - | - |
Citius Pharmaceuticals, Inc. reported operating cash flow of -$26.55M for fiscal year 2025. That is up 5.8% from -$28.20M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.90M (FY 2016) to -$26.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $33.30M | $9.97M | $13.83M | - | $120.47M | $22.90M |